MedTrace Logo

Bioavailability of Prochlorperazine Suppositories, 25 mg

NCT00992472 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2021-10-21

No results posted yet for this study

Summary

The purpose of this study is to compare prochlorperazine plasma concentrations produced after administration of the test formulation with those produced after administration of a marketed reference product.

Conditions

  • Healthy

Interventions

DRUG

Prochlorperazine suppositories, 25mg

DRUG

Compazine® suppositories, 25mg

Sponsors & Collaborators

  • Padagis LLC

    lead INDUSTRY

Principal Investigators

  • Ferguson, M.D. · PharmaKinetics Laboratories Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00992472 on ClinicalTrials.gov